GPCR Screening Identifies Long-Acting Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing G-protein coupled receptor (GPCR) ligands do not effectively distinguish between different receptor states, leading to unclear binding mechanisms and varying activity durations, particularly for parathyroid hormone (PTH) and PTH-related protein (PTHrP) analogs, which are crucial for treating conditions like osteoporosis and hypoparathyroidism.
Innovation Solution
A method is developed to differentiate between GPCR states (RG and R0) by measuring the affinity of candidate compounds to these states, allowing for the identification of long-acting or short-acting agonists, using techniques such as competition binding assays and delayed cAMP assays, to determine their therapeutic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PTH(1-34) is administered with prolonged duration, then bone-forming effects are enhanced, but bone-resorptive effects increase leading to net catabolic effect
Solution Approach 1:
The patent modifies the duration parameter of PTH receptor activation by developing analogs with altered pharmacokinetic properties. Long-acting analogs maintain activation for extended periods to promote bone formation, while short-acting analogs provide brief activation to avoid catabolic effects, thus optimizing the therapeutic window.
Solution Approach 2:
The patent utilizes pulsatile administration strategies where PTH analogs are delivered in periodic pulses rather than continuous infusion. This periodic action allows the receptor to experience intermittent activation that favors anabolic responses while preventing sustained activation that would trigger catabolic pathways.
2Device complexity
If current GPCR assessment methods are used, then screening process is simplified, but ability to distinguish between different receptor states and activity durations is lost
Solution Approach 1:
The patent segments the GPCR assessment into distinct components by developing separate assay systems that specifically detect different receptor states (e.g., G-protein coupled vs. uncoupled states). This segmentation allows precise differentiation of ligand properties while maintaining manageable complexity through modular assay design.
Solution Approach 2:
The patent introduces intermediary measurement systems such as reporter genes or fluorescent probes that mediate between the receptor state and the detection signal. These intermediaries enable precise discrimination of different receptor conformations and ligand binding states without requiring direct observation, thus enhancing measurement precision while keeping the overall system tractable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the identification of ligands with prolonged or short-lived activities, optimizing treatment frequency and efficacy for conditions like osteoporosis and hypoparathyroidism, by stabilizing specific receptor conformations and enhancing signaling responses.
Implementation Method 1
GPCR signaling requires that the G-protein be directly activated by the receptor, i.e., the RG state must form, and this RG formation can be induced by binding of an agonist ligand
Implementation Method 2
Binding of an agonist ligand induces or stabilizes the RG state, and reciprocally, the RG state stabilizes the high affinity binding of an agonist
Implementation Method 3
Upon binding GTP, or, a non-hydrolyzable GTP analog, such as GTPγS, a receptor-coupled G protein will dissociate from the receptor, causing the receptor to revert to a low affinity state
Implementation Method 4
some GPCRs, like the PTHR, can form a novel state (R0) that can bind certain agonist ligands with high affinity even in the presence of GTPγS
Data Source
AI summary
The present invention relates to a polypeptide, or pharmaceutically acceptable salt thereof, comprising the formula PTH(1-X)/PTHrP(Y-36). Further, the present invention refers to a polypeptide which binds the PTH receptor and has a high affinity for the R0 form of the PTH receptor and to a polypeptide having affinity for PTH RG and a low affinity for PTH R0. Moreover, the present invention includes to a pharmaceutical composition comprising such polypeptide. The present invention further relates to a polypeptide or a pharmaceutical composition of the present invention for use in a method for treating a disease or condition. Moreover, the present invention refers to a nucleic acid comprising a sequence encoding a polypeptide of the present invention, a vector comprising said nucleic acid, a cell comprising said vector and a method of making a polypeptide of the present invention. Finally, the present invention further relates to a method for determining whether a candidate compound is a long-acting agonist of a G protein coupled receptor (GPCR).